B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Phase 1
32
about 4.7 years
≤21
1 site in TN
What this study is about
Researchers are testing a new treatment called B7-H3 CAR T cells to see if it can help children with certain types of solid tumors. The trial will evaluate the safety and how well this treatment works in kids aged 18 or younger who have relapsed or refractory B7-H3+ solid tumors. It aims to determine the maximum safe dose of these CAR T cells.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take B7-H3 CAR T cells
- 2.Take Cyclophosphamide
- 3.Take Fludarabine
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cell therapy (Engineered T-cells that target specific cancer antigens), cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, mesna
infusion, oral (Oral Tablet)
Secondary: Clinical Response
Oncology